Drug intelligence / Profile preview

NIT 004

Development stage: Preclinical
Lead developer: NOVAiCOS Immunotherapeutics
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems

Overview

NIT 004 is a preclinical therapeutic candidate developed by NOVAiCOS Immunotherapeutics for the treatment of bone metastases. The drug is based on an ICOS-Fc fusion protein technology platform and is delivered using a specialized nanobead delivery system. ICOS (Inducible T-cell costimulator) is a member of the CD28/CTLA-4 family, and its ligand (ICOSL) is expressed on various cells, including those in the bone microenvironment. NIT 004 is designed to modulate the ICOS/ICOSL pathway to address the progression of metastatic disease in the bone microenvironment.

Targets

ICOSLG (Inducible T-cell Co-stimulator Ligand)

Beyond the preview

Go deeper on NIT 004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NIT 004.

Explore the full profile